Literature DB >> 28456588

Potential for low-value palliative care of patients with recurrent head and neck cancer.

Marci L Nilsen1, Jonas T Johnson2.   

Abstract

Curative treatment for patients with advanced head and neck cancer can be associated with many side-effects, and many patients suffer from persistent treatment-related side-effects. Patients with recurrent cancer bear the burden of these effects along with additional symptoms attributed to the recurrent tumour. To better understand the benefits and burden of palliative treatments for patients with recurrent head and neck cancer, we reviewed the evidence on commonly used palliative treatments and their effect on quality of life. When used for palliative care purposes, chemotherapy and radiotherapy have limited effectiveness in improving quality of life. Moreover, if these treatments are not congruent with a patient's end-of-life goals, they could constitute low-value care. We recommend that patients with advanced and recurrent cancer should be offered early, comprehensive palliative and supportive services to maximise benefit. The principles of beneficence and respect for patients in the context of shared decision making must prevail if the trust of this vulnerable patient population is to be honoured.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28456588     DOI: 10.1016/S1470-2045(17)30260-7

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  8 in total

1.  Palliative Head and Neck Cancer Treatment for Asymptomatic Disease.

Authors:  Divya Yerramilli; Kevin J Kovatch; Annie W Chan; Paul Swiecicki; Danielle N Margalit; Andrew G Shuman
Journal:  Otolaryngol Head Neck Surg       Date:  2018-02-27       Impact factor: 3.497

2.  Chemotherapy Use, End-of-Life Care, and Costs of Care Among Patients Diagnosed With Stage IV Pancreatic Cancer.

Authors:  Yuhua Bao; Renee C Maciejewski; Melissa M Garrido; Manish A Shah; Paul K Maciejewski; Holly G Prigerson
Journal:  J Pain Symptom Manage       Date:  2017-12-11       Impact factor: 3.612

3.  HER2-Targeted Multifunctional Silica Nanoparticles Specifically Enhance the Radiosensitivity of HER2-Overexpressing Breast Cancer Cells.

Authors:  Haruka Yamaguchi; Kazuhide Hayama; Ichiro Sasagawa; Yasuo Okada; Tomoyuki Kawase; Norio Tsubokawa; Makoto Tsuchimochi
Journal:  Int J Mol Sci       Date:  2018-03-19       Impact factor: 5.923

4.  [Randomized controlled trial for palliative radiotherapy of head and neck cancer-challenges remain].

Authors:  Alexander Fabian; David Krug; Jürgen Dunst
Journal:  Strahlenther Onkol       Date:  2020-11       Impact factor: 3.621

5.  Systematic Analysis of Molecular Subtypes and Immune Prediction Based on CD8 T Cell Pattern Genes Based on Head and Neck Cancer.

Authors:  Li Yanwei; Feng He; Shuang Liu; Zhanyu Pan
Journal:  J Oncol       Date:  2022-08-25       Impact factor: 4.501

6.  A qualitative examination of patient priorities and preferences during treatment decision-making for recurrent head and neck cancer.

Authors:  Bethany A Rhoten; Jessie I Sellers; Breanna Baraff; Kelly H Holler; Sheila H Ridner
Journal:  Support Care Cancer       Date:  2020-05-06       Impact factor: 3.603

Review 7.  Quality Assessment in Supportive Care in Head and Neck Cancer.

Authors:  Pierluigi Bonomo; Alberto Paderno; Davide Mattavelli; Sadamoto Zenda; Stefano Cavalieri; Paolo Bossi
Journal:  Front Oncol       Date:  2019-09-18       Impact factor: 6.244

8.  Patient-Reported Outcomes Assessing the Impact of Palliative Radiotherapy on Quality of Life and Symptom Burden in Head and Neck Cancer Patients: A Systematic Review.

Authors:  Alexander Fabian; Justus Domschikowski; Markus Hoffmann; Oliver Weiner; Claudia Schmalz; Jürgen Dunst; David Krug
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.